Logo image of OPT

OPTHEA LTD-SPON ADR (OPT) Stock Fundamental Analysis

NASDAQ:OPT - US68386J2087 - ADR

3.41 USD
+0.23 (+7.23%)
Last: 3/17/2025, 8:00:02 PM
Fundamental Rating

2

Overall OPT gets a fundamental rating of 2 out of 10. We evaluated OPT against 547 industry peers in the Biotechnology industry. Both the profitability and financial health of OPT have multiple concerns. OPT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OPT has reported negative net income.
OPT had a negative operating cash flow in the past year.
OPT had negative earnings in each of the past 5 years.
In the past 5 years OPT always reported negative operating cash flow.
OPT Yearly Net Income VS EBIT VS OCF VS FCFOPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

OPT's Return On Assets of -175.60% is on the low side compared to the rest of the industry. OPT is outperformed by 86.49% of its industry peers.
Industry RankSector Rank
ROA -175.6%
ROE N/A
ROIC N/A
ROA(3y)-138.57%
ROA(5y)-94.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OPT Yearly ROA, ROE, ROICOPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

OPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OPT Yearly Profit, Operating, Gross MarginsOPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

1

2. Health

2.1 Basic Checks

OPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
OPT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, OPT has more shares outstanding
The debt/assets ratio for OPT is higher compared to a year ago.
OPT Yearly Shares OutstandingOPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
OPT Yearly Total Debt VS Total AssetsOPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

OPT has an Altman-Z score of -9.32. This is a bad value and indicates that OPT is not financially healthy and even has some risk of bankruptcy.
OPT's Altman-Z score of -9.32 is on the low side compared to the rest of the industry. OPT is outperformed by 71.05% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.32
ROIC/WACCN/A
WACC9.32%
OPT Yearly LT Debt VS Equity VS FCFOPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

OPT has a Current Ratio of 1.57. This is a normal value and indicates that OPT is financially healthy and should not expect problems in meeting its short term obligations.
OPT's Current ratio of 1.57 is on the low side compared to the rest of the industry. OPT is outperformed by 81.23% of its industry peers.
OPT has a Quick Ratio of 1.57. This is a normal value and indicates that OPT is financially healthy and should not expect problems in meeting its short term obligations.
OPT has a Quick ratio of 1.57. This is amonst the worse of the industry: OPT underperforms 80.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.57
OPT Yearly Current Assets VS Current LiabilitesOPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.42% over the past year.
OPT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.06%.
The Revenue has been growing slightly by 2.88% on average over the past years.
EPS 1Y (TTM)16.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.76%
Revenue 1Y (TTM)-25.06%
Revenue growth 3Y22.04%
Revenue growth 5Y2.88%
Sales Q2Q%-60.45%

3.2 Future

Based on estimates for the next years, OPT will show a very strong growth in Earnings Per Share. The EPS will grow by 24.88% on average per year.
OPT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 384.85% yearly.
EPS Next Y56.03%
EPS Next 2Y33.14%
EPS Next 3Y24.08%
EPS Next 5Y24.88%
Revenue Next Year-37%
Revenue Next 2Y1620.09%
Revenue Next 3Y1036.13%
Revenue Next 5Y384.85%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OPT Yearly Revenue VS EstimatesOPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
OPT Yearly EPS VS EstimatesOPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OPT Price Earnings VS Forward Price EarningsOPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OPT Per share dataOPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as OPT's earnings are expected to grow with 24.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.14%
EPS Next 3Y24.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OPTHEA LTD-SPON ADR

NASDAQ:OPT (3/17/2025, 8:00:02 PM)

3.41

+0.23 (+7.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-28 2025-02-28/bmo
Earnings (Next)08-28 2025-08-28/amc
Inst Owners40.24%
Inst Owner Change-0.62%
Ins Owners1.22%
Ins Owner ChangeN/A
Market Cap524.75M
Analysts78
Price Target6.57 (92.67%)
Short Float %0.36%
Short Ratio13.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3%
PT rev (3m)19.52%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-75.68%
EPS NY rev (3m)-59.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-20%
Revenue NY rev (3m)-40%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5969.9
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0
BVpS-1.1
TBVpS-1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -175.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-138.57%
ROA(5y)-94.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 48.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.57
Altman-Z -9.32
F-Score1
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)21.93%
Cap/Sales(5y)17.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.76%
EPS Next Y56.03%
EPS Next 2Y33.14%
EPS Next 3Y24.08%
EPS Next 5Y24.88%
Revenue 1Y (TTM)-25.06%
Revenue growth 3Y22.04%
Revenue growth 5Y2.88%
Sales Q2Q%-60.45%
Revenue Next Year-37%
Revenue Next 2Y1620.09%
Revenue Next 3Y1036.13%
Revenue Next 5Y384.85%
EBIT growth 1Y-10.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.69%
EBIT Next 3Y15.54%
EBIT Next 5Y22.71%
FCF growth 1Y-46.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.8%
OCF growth 3YN/A
OCF growth 5YN/A